AU2001282377A1 - Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction - Google Patents

Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction

Info

Publication number
AU2001282377A1
AU2001282377A1 AU2001282377A AU8237701A AU2001282377A1 AU 2001282377 A1 AU2001282377 A1 AU 2001282377A1 AU 2001282377 A AU2001282377 A AU 2001282377A AU 8237701 A AU8237701 A AU 8237701A AU 2001282377 A1 AU2001282377 A1 AU 2001282377A1
Authority
AU
Australia
Prior art keywords
ikca
modulators
sexual dysfunction
channel activity
activated potassium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001282377A
Other languages
English (en)
Inventor
Christopher Peter Wayman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001282377A1 publication Critical patent/AU2001282377A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
AU2001282377A 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction Abandoned AU2001282377A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0021487.4 2000-09-01
GBGB0021487.4A GB0021487D0 (en) 2000-09-01 2000-09-01 Pharmaceutical
PCT/IB2001/001525 WO2002017963A2 (fr) 2000-09-01 2001-08-24 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
AU2001282377A1 true AU2001282377A1 (en) 2002-03-13

Family

ID=9898666

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001282377A Abandoned AU2001282377A1 (en) 2000-09-01 2001-08-24 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction

Country Status (6)

Country Link
EP (1) EP1313507A2 (fr)
JP (1) JP2004517046A (fr)
AU (1) AU2001282377A1 (fr)
CA (1) CA2420852A1 (fr)
GB (1) GB0021487D0 (fr)
WO (1) WO2002017963A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
NO20031157L (no) * 2002-03-18 2003-09-19 Jenapharm Gmbh Fremgangsmåte for å identifisere en farmasöytisk aktiv forbindelse for behandling av en tilstand forårsaket av forandret ekspresjon avinsulinreseptoren
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836546T2 (de) * 1997-07-15 2007-09-27 Astrazeneca Uk Ltd. Menschliches, durch kalzium aktivierbares kaliumkanalpolypeptid aus leukozyten
AU760250B2 (en) * 1998-12-04 2003-05-08 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6803375B1 (en) * 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
AU2001233052A1 (en) * 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor

Also Published As

Publication number Publication date
EP1313507A2 (fr) 2003-05-28
WO2002017963A2 (fr) 2002-03-07
WO2002017963A3 (fr) 2002-08-01
JP2004517046A (ja) 2004-06-10
GB0021487D0 (en) 2000-10-18
CA2420852A1 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
AU2002316516A1 (en) Vibrating personal massager
GC0000096A (en) Treatment of female sexual dysfunction.
HRP990195B1 (en) Intranasal formulations for the treatment of sexual disorders
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
AU2003248888A1 (en) Peptide composition for treatment of sexual dysfunction
AU2105901A (en) Treatment of eustachian tube dysfunction by application of radiofrequency energy
EP1121939A3 (fr) Traitement de l'ostéoporose par des agonistes sélectifs des récepteurs EP2/EP4
AU2002238106A1 (en) Melanocortin metallopeptides for treatment of sexual dysfunction
AU2001265839A1 (en) Use of potassium channel agonists for the treatment of cancer
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
AU3784999A (en) Methods for treatment of pain
AU2001290529A1 (en) Marital aid
AU3894600A (en) Method of treating sexual dysfunction
AU1986899A (en) Erotic massage device
AU2002212895A1 (en) N-type calcium channel antagonists for the treatment of pain
AU2001282377A1 (en) Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction
AU5509099A (en) Pyridinones for the treatment of sexual dysfunction
AU7652400A (en) Novel combination for the treatment of sexual dysfunction
AU2763299A (en) Treatment of brain edema using carbonic anhydrase enzyme inhibitor
AU2001284125A1 (en) Medicine for fighting against sexual dysfunction
PL362980A1 (en) Treatment of sexual dysfunction
AU2002222191A1 (en) Use of ep4 receptor agonists for treating neuropathic pain
AU2002336782A1 (en) Penis vibrator
AU2002365289A1 (en) Use of selective potassium channel openers
AU2002212896A1 (en) N-type calcium channel antagonists for the treatment of pain